A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in United Therapeutics Corp stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 32,092 shares of UTHR stock, worth $11.6 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
32,092
Previous 19,526 64.36%
Holding current value
$11.6 Million
Previous $6.22 Million 84.89%
% of portfolio
0.03%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$311.04 - $363.55 $3.91 Million - $4.57 Million
12,566 Added 64.36%
32,092 $11.5 Million
Q2 2024

Jul 29, 2024

BUY
$228.26 - $319.04 $4.46 Million - $6.23 Million
19,526 New
19,526 $6.22 Million
Q2 2023

Aug 08, 2023

BUY
$205.19 - $232.99 $219,348 - $249,066
1,069 Added 115.07%
1,998 $441,000
Q1 2023

May 08, 2023

BUY
$212.99 - $276.17 $197,867 - $256,561
929 New
929 $208,000
Q2 2022

Aug 04, 2022

BUY
$174.81 - $241.14 $4.51 Million - $6.22 Million
25,800 New
25,800 $6.08 Million
Q2 2019

Aug 02, 2019

SELL
$76.06 - $120.81 $512,111 - $813,413
-6,733 Closed
0 $0
Q1 2019

Apr 26, 2019

BUY
$107.15 - $126.84 $6,536 - $7,737
61 Added 0.91%
6,733 $790,000
Q4 2018

Feb 13, 2019

BUY
$101.4 - $128.73 $38,227 - $48,531
377 Added 5.99%
6,672 $701,000
Q3 2018

Nov 13, 2018

SELL
$113.81 - $129.46 $665,560 - $757,082
-5,848 Reduced 48.16%
6,295 $805,000
Q2 2018

Aug 01, 2018

SELL
$101.14 - $118.31 $747,829 - $874,784
-7,394 Reduced 37.85%
12,143 $1.37 Million
Q1 2018

May 07, 2018

BUY
$107.21 - $151.94 $1.21 Million - $1.71 Million
11,269 Added 136.3%
19,537 $2.2 Million
Q4 2017

Feb 01, 2018

BUY
$118.58 - $151.28 $294,078 - $375,174
2,480 Added 42.85%
8,268 $1.22 Million
Q3 2017

Nov 02, 2017

BUY
$114.6 - $136.81 $663,304 - $791,856
5,788
5,788 $678,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Bnp Paribas Asset Management Holding S.A. Portfolio

Follow Bnp Paribas Asset Management Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.